In the year-2 post-deal board meeting, someone finally asks: "of the $8M synergies promised, how much did we actually capture?" Silence. The team has no rigorous tracking. The CFO's informal estimate: "about half."
"About half" is the most honest and most expensive answer in M&A. Bain measures 60-70% of deals destroy value at 5 years — not because synergies are lies, but because the mix between cost (credible) and revenue (fantasy) gets assumed incorrectly and no one measures until it's late.
This module teaches you to distinguish synergies that get captured from those that get promised and never arrive. And, more importantly, to defend BEFORE signing why your mix is realistic — so you are not standing in the year-2 board with no answer.
By the end of this module you'll have it down. Let's go.
Your deal promised $10M annual synergies: $4M cost and $6M revenue. How much realistically should you expect at 36 months?
In plain language
Before the mechanics, the four basic questions.
Why do this at all?
To defend BEFORE signing (and report honestly AFTER) that promised synergies are credible. Without tracking discipline, the deal lives on faith — the board never knows if it worked. With tracking, each quarter compares realized vs promised and deviations trigger action.
Who captures and measures them?
The IMO (Module 5.3) captures them the first 100 days. Then transfers ownership to operating leaders by category. FP&A measures quarterly. CFO reports to board. Without explicit owners by category, synergies are everyone's responsibility — which in organizations means no one's.
When are they measured?
Design in due diligence. Validation pre-close. Quarterly tracking for 24-36 months post-close. Post-mortem in year 2 vs original deal case. If the deal delivered, learning for next ones. If not, lesson on which assumptions were wrong.
What if we do not measure?
Board never knows if the deal worked. Organization repeats the same errors in next deals because it did not learn. Goodwill impairs in year 3-4 without anyone seeing it coming. CFO loses credibility because defended the deal without being able to defend it after.
Andina + Tostadora del Sur — the deal at year 2
Recall the Tostadora del Sur deal (Modules 5.1-5.3): Andina paid $140M with an A/D case requiring $4M annual synergies to not destroy EPS. The IMO executed the 5 workstreams of the 100-day plan. We are at month 24 post-close.
The promised synergies were: $2M office consolidation, $1M combined procurement, $0.5M IT consolidation, $0.5M cross-sell of premium coffee to Andina's corporate clients. Total $4M.
Realized at month 24: $1.7M office consolidation (85% of promised), $0.6M procurement (60%), $0.3M IT (60%), $0.1M cross-sell (20%). Total $2.7M. Gap vs promise: $1.3M.
The Module 5.1 A/D with $4M synergies was 6% accretive in year 2. With $2.7M realized, it's marginal. If the team doesn't act NOW to accelerate the remainder or renegotiate the narrative to the board, year 3 closes dilutive.
The visual below shows the structural difference between cost (credible, ~75% capture) and revenue synergies (fantasy, ~25%). Move the mix slider and see how the deal changes dramatically.
Promise vs reality, live
Two curves over 36 months: promised (linear) and realized (logarithmic). The gap is the potential write-off.
Move "% in cost synergies" between 0 and 100. Watch how realized total changes drastically. This is the math your board should see BEFORE approving the deal — not in year 2 when it's already late.
Interactive visual
Synergies promised vs realized — the deal over 36 months
Move the weight between cost and revenue synergies. Watch the realized curve separate from promised. Cost ones deliver ~75%; revenue ones deliver ~25%.
Promised in deal
$8.0M
Realized total expected
$4.2M
52% capture
Gap (potential write-off)
−$3.8M
% in cost synergies
60%
60% cost synergies · 40% revenue synergies
Typical capture %
What you are seeing
Three critical lessons: (1) Synergies follow a logarithmic curve, not linear. The first 50% are easy (office consolidation, duplicate elimination); the last 50% are slow or unattainable. (2) The mix matters more than the total. A deal with 80% cost and 20% revenue synergies realizes at ~75%. The same deal with 30% cost and 70% revenue realizes at ~40% — half. (3) Revenue synergies are notoriously fantasy. Bain/McKinsey measure ~30% typical capture. If your A/D is only accretive with revenue synergies, the deal is a bet, not an investment.
Mature CFO rule: if your A/D is only accretive with revenue synergies dominant, the deal is calibrated on optimism, not reality. Renegotiate price or don't sign — but DO NOT defend a case that historically only delivers at 25%.
When you reach year 2 and the deal is below, the board's question should NOT be "why did synergies fail?". It should be "what synergies have we captured, what's missing, and what action is active?". If you can't answer that with quarterly numbers, you are not measuring — you are waiting for the problem to explode.
The mechanics: how to build capture discipline
- Each synergy with SINGLE owner. "Cost rationalization $2M = Juan." NOT "the operations team." Without single owner, no accountability — and without accountability, no capture.
- Rigorous categorization pre-close. Cost rat (duplicate consolidation, immediate savings) ≠ procurement (renegotiation, 6-12 months) ≠ IT (project, 12-18 months) ≠ revenue cross-sell (marketing + sales, 18-24 months) ≠ new product revenue (R&D + launch, 24-36 months). Each category has different curve.
- Capture rate adjusted by category. Do not assume 100% capture for anything. Cost rat: 80-85%. Procurement: 60-70%. IT: 50-60%. Cross-sell: 30-40%. New product: 15-25%. Realistic A/D is built with these adjustments, not with optimistic cases.
- Quarterly IMO tracking to board. One page: per category, promised / realized / gap / action. Without this, the board cannot judge.
- Post-mortem in year 2. Formal session with board: did the deal deliver the case? If not, which assumptions were wrong and what do we do differently next? Without this lesson, the company repeats the pattern.
- Learn for the next deal. If your mid-market repeatedly loses 30-40% of promised synergies, that 30-40% is your adjustment factor for next A/Ds. Pre-deal honesty costs less than post-deal surprise.
- Revenue cross-sell synergies. "Sell product A to B's customers." In model: $5M annually in year 2. In reality: 30-40% capture because sales processes are different, buyers are different, CSMs do not know each other.
- New-product revenue synergies. "Combine technical capabilities for innovative product." In model: $3M annually in year 3. In reality: 15-25% because products require R&D + go-to-market, 24-36 month cycles with no guarantee.
- "Combined talent" synergies. Almost never formally modeled. When modeled, almost never realized — the acquired company's key talent usually leaves in the first 12 months (Module 5.3).
- Practical rule: if your A/D has >50% in revenue synergies, discount the case to 50% of promised and re-evaluate. If still accretive, proceed. If not, renegotiate price or do not do the deal.
Adversarial check
Adversarial check
1.Your CEO presents a deal: "$5M of revenue cross-sell synergies, no cost synergies. A/D model: 8% accretive in year 2." What do you answer?
2.Month 18 post-deal. You have captured 50% of synergies promised for end of year 2. Your team says: "we are on track, the next 6 months we will close the rest." What do you decide?
3.Why do revenue synergies typically capture only 25-35%?
Exit checklist
Suggested re-review: every time you evaluate a deal with material synergies. Module 5.5 (LBO modeling) closes Pillar 5 with the financial-buyer angle.
Optional
Go deeper
Sources and books to dig into the original material